James Bauersmith, JD, MS

James is an experienced health care executive with more than 20 years of experience across a variety of health care segments. He joined UPMC Enterprises in August 2021 as vice president of Translational Sciences.

Before joining Enterprises, James was the chief strategic officer and general counsel of ByHeart, Inc., an infant formula company, where he led the company’s FDA strategy, managed all of their legal affairs, and led the acquisition and set-up of the company’s manufacturing facility. Prior to his role at ByHeart, James worked in the pharmaceutical sector for more than 15 years where he held a variety of leadership positions at Fresenius Kabi. There, he was the senior vice president, overseeing the company’s portfolio and marketing strategy unit. In his role at Amneal Pharmaceuticals, he oversaw the corporate development and procurement groups and was part of the executive management team.

Before his tenure at Fresenius and Amneal, James spent 10 years practicing law, first as an attorney in New York with Haug Partners, and then as in-house counsel at Teva Pharmaceuticals where he managed the company’s Hatch Waxman Patent litigations.

He earned a BS from the University of Notre Dame, a JD from the Pennsylvania State University School of Law, and an MS of bioscience and biotechnology from Drexel University. He is a registered U.S. Patent Attorney and maintains an active Pennsylvania law license.

At UPMC Enterprises, James focuses his time on identifying, analyzing, and structuring investment opportunities that address unmet therapeutic need and align with UPMC’s vision of bringing Life Changing Medicine to patients.